IDYA

IDEAYA Biosciences (IDYA) moved into focus after updated ESMO 2026 data for IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas, and for darovasertib in metastatic and primary uveal melanoma.

IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Leadership shift puts IDEAYA Biosciences in focus IDEAYA Biosciences (IDYA) has moved Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective 28 September 2026.

SOUTH SAN FRANCISCO, Calif., Sept.

Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation.

Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy OptimUM-11 expands development of darovasertib across the uveal melanoma…

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc.

Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential accelerated approval and median OS as the primary endpoint…

IDEAYA Biosciences, Inc.

IDEAYA Biosciences recently reported a second-quarter 2026 net loss of US$112.45 million, or US$1.22 per basic and diluted share, while also disclosing a wider six‑month loss versus the prior year.